国际妇产科联盟IV期卵巢癌初次与中间型肿瘤细胞减灭术的生存结局:一项全国性人群基础的目标试验模拟
基于法国国家健康保险数据库模拟目标试验,纳入2014年1月1日至2022年12月31日诊断的IV期卵巢癌患者2772例,初次肿瘤细胞减灭术1182例(42.6%),中间型1590例(57.4%)。初次手术较中间型手术5年无进展生存延长5.0个月(95%CI 3.8-6.2),7年总生存延长3.9个月(95%CI 1.9-6.2)。
要点
- 初次肿瘤细胞减灭术较中间型手术与更长的无进展生存和总生存相关。
- IV期卵巢癌中初次手术的生存获益在IVA和IVB亚组中均观察到。
- 胸膜、膈上或腹腔外淋巴结转移患者中初次手术也显示更优生存。
核心结论
- 本研究支持对IV期卵巢癌患者初次肿瘤细胞减灭术优于中间型肿瘤细胞减灭术。
- 作者认为膈上或腹腔外淋巴结等腹膜外转移不应自动排除合适患者考虑初次肿瘤细胞减灭术。
研究设计与样本
- 利用法国国家健康保险数据库模拟目标试验(SOFI-4),评估初次与中间型肿瘤细胞减灭术对IV期卵巢癌预后的因果影响。
- 采用克隆法结合逆概率删失加权调整信息性删失并平衡组间基线特征。
- 纳入年龄小于75岁、健康状况良好、2014年1月1日至2022年12月31日诊断的IV期卵巢癌患者2772例。
- 主要结局为5年无进展生存,次要结局为7年总生存,并按分期和腹膜外转移部位进行亚组分析。
主要发现
- 纳入2772例患者中,IVA期948例(34.2%),IVB期1824例(65.8%)。
- 初次肿瘤细胞减灭术1182例(42.6%),中间型肿瘤细胞减灭术1590例(57.4%)。
- 初次手术中位无进展生存19.7个月(四分位距19.3-20.1)vs 中间型手术15.7个月(四分位距15.7-16.1)。
- 初次手术中位总生存63.1个月(四分位距61.7-65.4)vs 中间型手术55.6个月(四分位距53.8-56.3)。
- 初次手术较中间型手术5年无进展生存增加5.0个月(95%CI 3.8-6.2),7年总生存增加3.9个月(95%CI 1.9-6.2)。
关键数值与推荐
- 初次手术较中间型手术的生存获益在IVA和IVB亚组中均观察到。
- 胸膜、膈上或腹腔外淋巴结转移患者中,初次手术显示更优的无进展生存和总生存。
临床怎么用
- 作者倡导对IV期卵巢癌患者优先考虑初次肿瘤细胞减灭术而非中间型肿瘤细胞减灭术。
- 作者建议膈上或腹腔外淋巴结等腹膜外转移不应自动排除合适患者考虑初次肿瘤细胞减灭术。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of primary cytoreductive surgery vs interval cytoreductive surgery on International Federation of Gynecology and Obstetrics stage IV ovarian cancer outcomes remains uncertain and may vary depending on the stage and the location of extraperitoneal metastasis. Emulating target trials through causal assessment, combined with propensity score adjustment, has become a leading method for evaluating interventions using observational data. OBJECTIVE: This study aimed to assess the effect of primary vs interval cytoreductive surgery on progression-free and overall survival in patients with International Federation of Gynecology and Obstetrics stage IV ovarian cancer using target trial emulation. STUDY DESIGN: Using the comprehensive French national health insurance database, we emulated a target trial to explore the causal impacts of primary vs interval cytoreductive surgery on stage IV ovarian cancer prognosis (Surgery for Ovarian cancer FIGO 4: SOFI-4). The clone method with inverse probability of censoring weighting was used to adjust for informative censoring and to balance baseline characteristics between the groups. Subgroup analyses were conducted based on the stages and extraperitoneal metastasis locations. The study included patients younger than 75 years of age, in good health condition, who were diagnosed with stage IV ovarian cancer between January 1, 2014, and December 31, 2022. The primary and secondary outcomes were respectively 5-year progression-free survival and 7-year overall survival. RESULTS: Among the 2772 patients included in the study, 948 (34.2%) were classified as having stage IVA ovarian cancer and 1824 (65.8%) were classified as having stage IVB ovarian cancer at inclusion. Primary cytoreductive surgery was performed for 1182 patients (42.6%), whereas interval cytoreductive surgery was conducted for 1590 patients (57.4%). The median progression-free survival for primary cytoreductive surgery was 19.7 months (interquartile range, 19.3-20.1) as opposed to 15.7 months (interquartile range, 15.7-16.1) for those who underwent interval cytoreductive surgery. The median overall survival was 63.1 months (interquartile range, 61.7-65.4) for primary cytoreductive surgery in comparison with 55.6 months (interquartile range, 53.8-56.3) for interval cytoreductive surgery. The findings of our study indicate that primary cytoreductive surgery is associated with a 5.0-month increase in the 5-year progression-free survival (95% confidence interval, 3.8-6.2) and a 3.9-month increase in 7-year overall survival (95% confidence interval, 1.9-6.2). These survival benefits of primary over interval cytoreductive surgery were observed in both the International Federation of Gynecology and Obstetrics stage IVA and IVB subgroups. Primary cytoreductive surgery demonstrated improved progression-free survival and overall survival in patients with pleural, supradiaphragmatic, or extra-abdominal lymph node metastasis. CONCLUSION: This study advocates for the benefits of primary cytoreductive surgery over interval cytoreductive surgery for patients with stage IV ovarian cancer and suggests that extraperitoneal metastases like supradiaphragmatic or extra-abdominal lymph nodes should not automatically preclude primary cytoreductive surgery consideration in suitable patients.
引用
- Jochum F, Dumas É, Gougis P, et al. Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation. Am J Obstet Gynecol. 2024. PMID: 39111517. doi:10.1016/j.ajog.2024.07.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。